Search results
Showing 1 to 15 of 85 results for antidepressants
Depression in adults with a chronic physical health problem: recognition and management (CG91)
This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Generalised anxiety disorder and panic disorder in adults: management (CG113)
This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Depression in children and young people: identification and management (NG134)
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
This quality standard covers the assessment and management of non-specific low back pain and sciatica in young people and adults aged 16 years and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS155Show all sections
Sections for QS155
- Quality statements
- Quality statement 1: Risk stratification
- Quality statement 2: Referrals for imaging
- Quality statement 3: Self-management
- Quality statement 4: Gabapentinoids, antiepileptics, antidepressants and paracetamol for low back pain without sciatica
- Quality statement 5: Opioids for chronic low back pain without sciatica
- Quality statement 6: Spinal injections
- Update information
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
Low back pain and sciatica in over 16s: assessment and management (NG59)
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
Repetitive transcranial magnetic stimulation for depression (HTG396)
Evidence-based recommendations on repetitive transcranial magnetic stimulation for depression. This involves placing an electromagnetic coil against the scalp, which creates electric currents in certain parts of the brain.
Irritable bowel syndrome in adults: diagnosis and management (CG61)
This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.
carers of people having treatment with an opioid, benzodiazepine, Z‑drug, antidepressant or gabapentinoid? Any explanatory notes(if...